Anastasios Koutsopoulos
Overview
Explore the profile of Anastasios Koutsopoulos including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
646
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kalogerakos P, Lasithiotakis K, Vernardos M, Lazopoulos L, Koutsopoulos A, Lazopoulos G
Oxf Med Case Reports
. 2022 Apr;
2022(3):omac031.
PMID: 35371517
Cardiac amyloidosis has been strongly associated with postoperative intractable circulatory failure, and intestinal amyloidosis could lead to intestinal pseudo-obstruction. The latter can be treated with neostigmine, which is notorious for...
2.
Kerdidani D, Aerakis E, Verrou K, Angelidis I, Douka K, Maniou M, et al.
J Exp Med
. 2022 Jan;
219(2).
PMID: 35029648
A key unknown of the functional space in tumor immunity is whether CD4 T cells depend on intratumoral MHCII cancer antigen recognition. MHCII-expressing, antigen-presenting cancer-associated fibroblasts (apCAFs) have been found...
3.
Papadakis B, Vorrias E, Brautigam K, Chochlidakis N, Koutsopoulos A, Mavroudis D, et al.
J Clin Neurosci
. 2021 Oct;
93:168-173.
PMID: 34656242
A tumor-to-tumor metastasis inside a meningioma is a rare phenomenon. Malignant neoplasms of the breast and lung are the most common primary tumors. Other sites of origin include prostate, renal...
4.
Thomopoulou K, Manolakou S, Messaritakis I, Tzardi M, Lagoudaki E, Koutsopoulos A, et al.
Ann Gastroenterol
. 2020 Jan;
33(1):95-97.
PMID: 31892804
Despite the development of new treatment options based on the molecular characterization of colorectal cancer, 20% of patients present de novo metastatic disease, whereas 30-40% of patients who receive curative...
5.
Messaritakis I, Nikolaou M, Koinis F, Politaki E, Koutsopoulos A, Lagoudaki E, et al.
Lung Cancer
. 2019 Aug;
135:33-39.
PMID: 31447000
Objectives: The aim of the study was to characterize and evaluate the presence of DLL3-positive Circulating Tumor Cells (CTCs) in SCLC patients receiving front-line chemotherapy and assess their clinical relevance....
6.
Kallergi G, Tsintari V, Sfakianakis S, Bei E, Lagoudaki E, Koutsopoulos A, et al.
Breast Cancer Res
. 2019 Aug;
21(1):86.
PMID: 31370904
Background: Circulating tumor cells (CTCs) are important for metastatic dissemination of cancer. They can provide useful information, regarding biological features and tumor heterogeneity; however, their detection and characterization are difficult...
7.
Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrri A, Mavroudis D, et al.
Mol Oncol
. 2019 Jun;
13(12):2515-2530.
PMID: 31254443
Liquid biopsy analysis, mainly based on circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA), provides an extremely powerful tool for the molecular profiling of cancer patients in real time....
8.
Kotsakis A, Kallergi G, Aggouraki D, Lyristi Z, Koinis F, Lagoudaki E, et al.
Ther Adv Med Oncol
. 2019 Jun;
11:1758835919853193.
PMID: 31217824
Background: Since tumor cells may escape from immune surveillance through the programmed cell death 1 (PD-1)/programmed death ligand (PD-L)1 axis, this study was designed in order to evaluate whether there...
9.
Messaritakis I, Nikolaou M, Politaki E, Koinis F, Lagoudaki E, Koutsopoulos A, et al.
Lung Cancer
. 2018 Oct;
124:270-278.
PMID: 30268472
Introduction: To investigate the presence of Bcl-2CTCs in chemotherapy-naïve SCLC patients and their clinical relevance during front-line treatment. Methods: Peripheral blood was obtained from 66 consecutive-patients before chemotherapy administration, after...
10.
Kallergi G, Vetsika E, Aggouraki D, Lagoudaki E, Koutsopoulos A, Koinis F, et al.
Ther Adv Med Oncol
. 2018 Feb;
10:1758834017750121.
PMID: 29383038
Background: Circulating tumor cells (CTCs) could escape from the immune system through the programmed death-ligand 1 (PD-L1)/programmed cell death protein 1 (PD-1) axis leading to the development of metastasis. The...